Q2 2025

Filed Aug 7, 2025 · 10-Q · 38 days after period end · 0001493152-25-011685

Q2 2025 · 10-Q

Revenue—

Net Income

-$3.93M

N/M vs Q2 2024

EPS Diluted

-$6.26

N/M vs Q2 2024

Operating Income-$3,950,783N/M

Operating Cash Flowderived-$2,270,405N/M

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	—	—	$0.00	$0.00
Net Income	-$3.93M	-$3.01M	-$2.61M	-$5.16M
EPS Diluted	-$6.26	-$1.01	-$1.94	-$0.32

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR